September 10, 2018
Ceremony marks launch of SJTU-Yale Immune-metabolic Research Center
Yale University and Shanghai Jiao Tong University (SJTU) launched the SJTU-Yale Immune-metabolic Research Center (SYIRC) at a ceremony at the SJTU School of Medicine on Sept. 11. The signers in attendance were Donald Filer, associate vice president for global strategy at Yale University, and Fan Jiang, vice-chancellor of Shanghai Jiao Tong Medical School (SJTUMS). Witnesses of the signing ceremony included Professor Bing Su, director of the SYIRC; Chancellor Chen Guoqing of SJTUMS; Deputy Dean Michael C. Crair of the Yale School of Medicine (YSM); and Richard A. Flavell, the Sterling Professor of Immunobiology at YSM and an investigator at the Howard Hughes Medical Institute.
​
This articles is republished from Yale News (https://news.yale.edu/2018/09/11/ceremony-marks-launch-sjtu-yale-immune-metabolic-research-center). For questions,please contact Yale News at news@yale.edu(mailto:news@yale.edu) or 203-432-1345.
​
...
March 02, 2018
Professor Richard A. Flavell From School of Medicine, Yale University visited our hospital
On the morning of December 12th, Academician Chen Guoqiang, the dean of the Shanghai Jiaotong University School of Medicine, invited Professor Richard A. Flavell a member of the National Academy of Sciences, a fellow of the Royal Society, and the Founder of Department of Immunology, School of Medicine of the Yale University to visit our institute and give the 21st Century Innovation Forum Special Field Report: Inflammation, Microbiota and Human Health.
March 02, 2018
Huabing Li lab revealed m6A mRNA methylation sustains Treg suppressive functions
The results show that the m6A RNA modification specifically targets the same class of genes encoding components of essential signaling pathways in different T cell subtypes, thereby controlling the differentiation of naïve T cells and also sustaining the suppressive functions of Tregs. Since Tregs in the tumor microenvironment suppress the tumor-killing functions of CD8 T cells, it is possible that selective depletion of m6A in tumor-infiltrated Tregs may be beneficial in combination with other forms of cancer immunotherapy.